A Phase 1 Food-Effect Study of 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects

Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The objective of this phase 1 study is to evaluate the food effect of 100 mg Hezkue Turbo® (ASP-001.1, sildenafil) under fed versus 100 mg of Hezkue Turbo® (ASP-001.1, sildenafil) under fasted conditions in healthy adult male subjects

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 20
Maximum Age: 70
Healthy Volunteers: t
View:

• The participant must be informed of the nature of the study and voluntarily agree to participate by signing an informed consent form prior to any study-specific procedures.

• Participants must be healthy male volunteers aged 20 to 70 years (inclusive) at the time of dosing.

• Participants must have a body mass index between 18.0 and 29.9 kg/m² (inclusive) and a body weight of 50 to 100 kg (inclusive).

• Participants must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG). Any deviations from normal ranges must be assessed and deemed not clinically significant by the Investigator or designee.

• Participants must have a creatinine clearance (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation.

• Participants must agree to practice an acceptable method of contraception as outlined in the protocol.

Locations
United States
New York
Aspargo Labs
RECRUITING
New York
Time Frame
Start Date: 2025-04-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 12
Treatments
Experimental: Arm 1 - Fasted vs Fed Conditions
Participants receive 100mg of ASP-001.1 first under fasted conditions and under fed conditions after
Experimental: Arm 2- Fed vs Fasted Conditions
Participants receive 100mg of ASP-001.1 first under fed conditions and under fasted conditions after
Related Therapeutic Areas
Sponsors
Leads: Aspargo Labs, Inc

This content was sourced from clinicaltrials.gov